Article Information
History
- September 25, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Fasihul A Khan1,2,
- Iain Stewart1,2,3,
- Samuel Moss1,2,3,
- Laura Fabbri1,2,3,
- Karen A. Robinson4,
- Simon Johnson1,2 and
- R Gisli Jenkins1,2,3,*
- 1Division of Respiratory Medicine, School of Medicine, University of Nottingham, Nottingham, UK
- 2Nottingham Biomedical Research Centre, National Institute for Health Research, UK
- 3National Health and Lung Institute, Imperial College London, London, UK
- 4Johns Hopkins University, Baltimore, Maryland, USA
- ↵*Correspondence to:
Professor Gisli Jenkins – gisli.jenkins{at}imperial.ac.uk
Author contributions FK: conceptualisation, data curation, methodology, formal analysis, writing – original draft
IS: conceptualisation, formal analysis, methodology, supervision, writing – original draft SM: formal analysis, writing – reviewing and editing
LF: data curation, writing – reviewing and editing
KR: methodology, writing – reviewing and editing
SJ: methodology, writing – reviewing and editing
GJ: conceptualisation, funding acquisition, methodology, supervision, writing – original draft
Posted September 25, 2021.
Three month FVC change: a trial endpoint for IPF based on individual participant data meta-analysis
